QbD Group
    Regulatory Update

    EU Pharmacovigilance: Implementing Regulation (EU) 2025/1466

    The European Commission has amended Regulation (EU) No 520/2012 on pharmacovigilance. The update strengthens oversight of outsourced PV activities, clarifies EudraVigilance monitoring, and aligns processes with international data standards (IDMP, MedDRA, Standard Terms).

    Key updates

    PV outsourcing

    Contracts must define roles, data exchange, audit/inspection rights, and prohibit onward subcontracting without written consent. Third parties must accept audits and may be inspected by regulators.

    Audits

    Risk-based audits must cover all PV activities, including subcontracted work.

    EudraVigilance

    MAHs must monitor EV alongside other sources; authorities must monitor EV continuously. Signals needing further analysis must be confirmed within 30 days.

    Data & reports

    Updated requirements for ICSR minimum elements, literature references (with DOI), PSURs (RMM implementation/effectiveness), and PASS registration in EMA’s PAS register.

    PSMF

    Focus only on major/critical deviations, their impact, and resolution.

    What does this mean to you?

    This amendment closes long-standing operational gaps: it codifies what many inspectors already expect on third-party control, tightens signal management timelines, and pushes convergence with IDMP and robust RMM effectiveness reporting. MAHs should update contracts, refresh audit plans, and adapt SOPs for EV monitoring and reporting.

    Changes take effect from 12 February 2026, so preparations should begin now.

    关于作者

    Almudena del Castillo
    Almudena del Castillo

    Division Head Vigilance

    Almudena leads pharmacovigilance strategy and operations at QbD Group as Division Head of Vigilance, helping pharma and biotech companies build robust drug safety systems.

    Regulatory Affairs services

    Navigate Regulatory Complexity with Confidence

    Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.

    Read more
    分享本文

    订阅生命科学领域的最新动态

    专家观点直达您的收件箱——选择您的兴趣。

    绝无垃圾邮件。随时取消订阅。

    继续阅读

    相关内容

    我们使用 Cookie 来改善您的体验

    我们使用必要的 Cookie 来保证网站功能,以及可选的分析 Cookie 来改善我们的服务。 阅读我们的 隐私政策Cookie 政策.